Latest Breaking News On - Winship cancer institute of emory university - Page 1 : comparemela.com

FDA Grants Osimertinib Priority Review for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer

Osimertinib demonstrates improved progression-free survival for stage 3 epidermal growth factor receptor-mutated (EGFRm) lung cancer.

Suresh ramalingamOsimertinib tagrissoNational cancer instituteWinship cancer institute of emory universityExecutive directorWinship cancer instituteEmory universityNew standard

Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Kevin kalinskyGlenn family breast centerDivision of medical oncologyBreast cancer researchDepartment of hematologyWinship cancer institute of emory universityEmory university school of medicineMedical oncologyEmory university schoolRand glenn family chairBreast medical oncologyWinship cancer instituteEmory university

Osimertinib New Standard of Care for Stage 3, EGFRm NSCLC

Osimertinib New Standard of Care for Stage 3, EGFRm NSCLC
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

United statesSuresh ramalingamSebastian kaulitzkiDavid spigelAmerican society of clinical oncology annual meetingWinship cancer institute of emory universitySarah cannon research instituteAmerican society of clinical oncologyClinical oncologyWinship cancer instituteEmory universityNew england journalProgression free survivalCrossover therapySite briefingClinical oncology annual meeting

Osimertinib delays progression way more than hoped in EGFR -mutant lung cancer

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO

United statesJosh friedmanSureshs ramalingamMindy valcarcelOsimertinib tagrissoJulier gralowDavidr spigelByjosh friedmanWinship cancer institute of emory universitySarah cannon research instituteWinship cancer instituteEmory university

Osimertinib Offers 84% Improvement in PFS Over Standard of Care in Stage III Unresectable EGFR-Driven NSCLC

A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer.

United statesLauren byersSureshs ramalinganDavidr spigelWinship cancer institute of emory universityMd anderson cancer centerAmerican society of clinical oncologySarah cannon research instituteAmerican societyClinical oncologyWinship cancer instituteEmory universityNew england journalAmerican journalNeck medical oncologyCancer center